12+1 Anniversary

We are now celebrating our “twelve plus one” anniversary with StageBio. A twelve plus one company anniversary is a confirmation of the successful performance of TPL and its employees along with StageBio company, because it marks a long and eventful period with many high points.

StageBio has contributed to the fact, and this is the key to success, that we can celebrate our twelve plus one company anniversary today.

For this, a very heartfelt thank you, to our CEO, Tom Galati, all team members, and our clients for many further years of trust and fair cooperation. # thankyou

StageBio Announces new Director of Digital and Quantitative Pathology: Dr. Thomas Lemarchand

StageBio is excited to introduce you to our new Director of Digital and Quantitative Pathology, our very own Dr. Thomas Lemarchand!

Dr. Lemarchand brings a wealth of experience and passion to this role.  As an experienced research and preclinical pathologist, he has broad expertise in molecular and immunopathology, disease models, GLP studies and clinical trials. With years of practice in projects involving in situ hybridization, immunohistochemistry, immunofluorescence and morphometry, he is perfectly positioned to lead this computational pathology program.

Under Dr. Lemarchand’s leadership, StageBio’s digital pathology initiative will be focused on deploying an efficient and user friendly image management and sharing platform for internal users and StageBio clients.  Additionally, he’ll accelerate the roll-out of StageBio’s software components and assemble a core imaging team to create a premier pathology bioinformatics service supporting internal and external clients, across divisions and regions.

“We are delighted to have Thomas move to this leadership role with our team,” says Serge Rousselle, Chief Scientific Officer. “Integrating his experience and talent with leading the digital pathology initiative is the natural next step, and it will continue to support our vision of excellence at StageBio.”

Please join the StageBio team in congratulating Dr. Thomas Lemarchand on his new role, Director of Digital and Quantitative Pathology!

 

About Dr. Thomas Lemarchand

Dr. Thomas Lemarchand performed research in molecular and immunopathology in disease models and worked in pharmaceutical companies, before leveraging this experience in both GLP safety and pharmacology non-GLP studies in CROs. As Director of Digital and Quantitative Pathology at StageBio, Dr. Lemarchand routinely uses in situ hybridization, immunohistochemistry, immunofluorescence and morphometry in studies. He earned his DEDV (DMV) from Nantes University School of Veterinary Medicine in 1992, completed pathology training in 1993 in Montreal and earned his PhD from Louisiana State University in 2000. He became a Diplomate of the European College of Veterinary Medicine in 2015.

About StageBio

StageBio is a leading provider of GLP-compliant necropsy, histology, pathology, and specimen archiving services for the biopharmaceutical, medical device, academic, and contract research industries. The company operates six GLP laboratories as well as two GLP specimen archiving facilities in the U.S., with substantial continued investment in facility and technology infrastructure to meet the growing demand for high-quality histopathology services globally. StageBio has a team of 25+ board-certified veterinary pathologists and more than 60 laboratory technicians on staff supporting our unified commitment to quality, scientific integrity and client satisfaction.

 

Learn more at stagebio.com

TPL Path Labs has now merged with StageBio

TPL Path Labs is now a part of StageBio, a leading provider of GLP-compliant necropsy, histology, image analysis, pathology and specimen archiving services based in the United States.  Learn how we are expanding our ability to serve you.  Link to:  https://www.stagebio.com/tpl-acquisition

 

Read the full press release here

Immuno-oncology 4-plex panel & digital pathology (Visiopharm®)

We are happy to develop your customized multiplex IHC protocols for your preferred combination of targets upon request.

Using a four-marker antibody panel, we have implemented a multiplex IHC method allowing for chromogenic multicolor detection of immune checkpoint ligand PD-L1, T lymphocyte markers CD4 and CD8, and regulatory T cell marker FoxP3 in human FFPE tissue sections. The method runs fully automated on our Ventana Discovery Ultra platform and can be optimized for your desired type of tissue. For your highest output of information we perform digital image analysis (Visiopharm®) on multiplex-stained sections to allow for staining quantification, distribution, co-localization and more.

T cell-mediated immunity plays a critical role in the control of tumor development. An intricate network of interactions between tumor cells, effector T cells and regulatory T cells can keep T cell-mediated anti-tumor response in check, eventually allowing the tumor to evade the hosts immune system. Simultaneous analysis/investigation of both immune checkpoint and phenotyping markers by multiplex IHC provides insight into infiltration, relative localization, and potential interactions of different cell types. Therefore, multiplex IHC greatly supports immuno-oncology research and drug development.

A novel human ex-vivo burn model and the local coling effect of a bacterial nanocellulose-based wound dressing

TPL Path Labs is proud to have contributed with its histopathological expertise in a novel human ex-vivo burn model project:

 

Background: Burn wound progression is a significant problem as burns initially thought to be superficial can actually become full thickness over time. Cooling is an efficient method to reduce burn wound conversion. However, if the cooling agent is below room temperature, depending on the wound size the patient is at risk of hypothermia.

 

View Full-Text

Antimicrobial Silver Multilayer Coating for Prevention of Bacterial Colonization of Orthopedic Implants

TPL Path Labs is proud to have contributed with our histopathological expertise.

 

Well done, Thomas Lemarchand and many thanks to all others!

 

A modified infection model using silver multilayer (SML) coating showed massive decrease of antimicrobial activity in vitro, and pathogen reduction with a complete cure rate of 58% in an in vivo osteomyelitis model in rabbits.

View Full-Text